A practical reference on NAD+: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-11-29 and is reviewed periodically as new material appears.
Research interest in NMN increased after animal studies reported that oral or injected NMN can raise NAD+ levels in some tissues. How NMN is absorbed and distributed in humans is not fully established. Some evidence suggests extracellular NMN may be dephosphorylated to nicotinamide riboside before cellular uptake, while other studies propose specific transport routes. Direct human data on these mechanisms remain limited. Regulatory status also varies: in some countries NMN is treated as a dietary supplement, while elsewhere it is restricted or requires approval, and these differences affect labeling, sale, and research.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms. Its structure consists of a nicotinamide group linked to a ribose sugar that carries a phosphate group. NMN is an intermediate in the biosynthesis of nicotinamide adenine dinucleotide, or NAD+, a coenzyme involved in many metabolic reactions. The abbreviation usually refers to the beta anomer, though related forms can exist. In scientific literature, NMN is distinct from nicotinamide riboside, another NAD+ precursor.
In the canonical salvage pathway, nicotinamide phosphoribosyltransferase, known as NAMPT, transfers a phosphoribosyl group to nicotinamide and releases NMN. A second enzyme, NMN adenylyltransferase, then attaches an adenylyl group to NMN to form NAD+. Alternative routes exist, including a pathway that uses nicotinamide riboside and its phosphorylated forms. The relative contribution of extracellular NMN to intracellular NAD+ pools remains an area of active investigation, and the roles of specific transporters and enzymes are not completely defined.
NMN is present in small amounts in various foods, including certain vegetables, fruits, and milk, though dietary quantities are generally low. Laboratory research often uses synthetic or enzymatically produced NMN. The compound has drawn interest because NAD+ levels decline with age in some tissues and because restoring NAD+ may affect metabolism in animal models. Whether oral NMN produces meaningful NAD+ increases in humans and whether such changes translate into health benefits are not fully established.
| Property | Value | Notes |
|---|---|---|
| Chemical name | Nicotinamide mononucleotide | Common name; beta form often denoted beta-NMN |
| Chemical formula | C11H15N2O8P | As free acid; salt forms differ |
| Molar mass | 334.22 g/mol | Calculated for the free acid |
| CAS Registry Number | 1094-61-7 | For beta-nicotinamide mononucleotide |
| Biochemical role | NAD+ intermediate | Participates in the salvage biosynthesis pathway |
Small amounts of NMN occur in some foods, including certain vegetables, fruits, and animal products, though the quantities are generally low and variable. Human cells also synthesize NMN internally from nicotinamide and other precursors. Research interest increased after studies examined whether raising NAD+ levels affects metabolism and aging-related pathways in animals. Evidence in humans remains limited and mixed for many outcomes, and questions about effective absorption, tissue delivery, and long-term effects are still open. Regulatory status differs by country, with some markets treating NMN as a supplement ingredient and others restricting its sale.
Nicotinamide mononucleotide, usually shortened to NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide base linked to a ribose sugar that carries a phosphate group. In cells, NMN serves as an intermediate in the salvage pathway that produces nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in many oxidation-reduction reactions, NMN sits near central metabolic processes. The compound is not a drug in most jurisdictions and is discussed mainly in biochemistry and nutrition research.
In the salvage pathway, NMN is generated from nicotinamide and 5-phosphoribosyl-1-pyrophosphate by the enzyme nicotinamide phosphoribosyltransferase. A second route produces NMN from nicotinamide riboside through phosphorylation by nicotinamide riboside kinases. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferases, often called NMNAT enzymes. This stepwise route allows cells to recycle nicotinamide and maintain NAD+ levels under changing metabolic conditions. The relative contribution of each route varies by tissue, species, and physiological state, and it remains an active area of research.
Research on NMN has expanded because NAD+ concentrations decline with age in some tissues and because NAD+ participates in energy metabolism, DNA repair, and signaling. Animal studies have reported changes in NAD+ levels after NMN administration, but human data are more limited and often focus on safety, pharmacokinetics, and biomarker changes. Questions remain about oral absorption, tissue distribution, and whether changes in blood NAD+ reflect changes inside specific organs. NMN is not an approved drug, and claims about its clinical effects should be distinguished from established biochemical findings.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide ring with a ribose sugar and a phosphate group. The compound appears in cells across many organisms as an intermediate in the production of nicotinamide adenine dinucleotide, or NAD+. Because NMN sits close to NAD+ in metabolism, it has drawn interest in biochemistry and aging research. The molecule is not a dietary essential nutrient in the classical sense, and its presence in food is generally low and variable.
NAD+ serves as a coenzyme in redox reactions and as a substrate for enzymes involved in DNA repair and cellular signaling. In the salvage pathway, nicotinamide is converted to NMN by the enzyme NAMPT. NMN is then converted to NAD+ by NMNAT enzymes. A separate route links nicotinamide riboside to NMN through phosphorylation. These pathways maintain NAD+ levels, which can decline with age or metabolic stress in some tissues. The relative contribution of circulating NMN to tissue NAD+ remains an active area of study.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a pyridine nucleotide that consists of a nicotinamide ring, a ribose sugar, and a phosphate group. It is an intermediate in the salvage pathway for nicotinamide adenine dinucleotide, or NAD+, synthesis. In mammalian cells, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. Nicotinamide mononucleotide adenylyltransferases then convert NMN into NAD+. The core structure and enzymatic route are well established in biochemical literature.
The biologically relevant form of NMN is generally the beta anomer, which is recognized by NMN adenylyltransferases. NMN is polar and water soluble, and it does not readily diffuse across lipid membranes without assistance. Whether intact NMN enters cells through a specific transporter remains an open question; some studies propose solute carrier family members, while other work favors extracellular dephosphorylation to nicotinamide riboside followed by uptake. This transport and compartmentalization debate affects how researchers interpret oral administration studies. The distinction between intracellular synthesis and extracellular delivery is central to current discussion.
Terminology around NMN can be confusing because several related compounds share the vitamin B3 family. Nicotinamide riboside is a nucleoside, whereas NMN is a nucleotide with a phosphate group, and NAD+ is a dinucleotide coenzyme rather than a simple precursor. Niacin and nicotinamide are also NAD+ precursors but follow different metabolic entry points. In commercial and scientific writing, NMN usually refers to beta-nicotinamide mononucleotide unless another form is specified. Consistent nomenclature helps distinguish chemical identity from proposed biological effects.
glutathione disulfide + protein-dithiol Thus, the two substrates of this enzyme are glutathione and protein disulfide, whereas its two products are glutathione disulfide and protein dithiol. In humans, at least one protein, TXNDC12, is thought to have enzyme activity of this type based on relatively recent data (2003). Historically, the breaking of the disulfide bonds of insulin was thought to be catalyzed by an enzyme of this class, which researcher’s called “glutathione-insulin transhydrogenase” (GIT). Later, the enzyme in question was found to be of the protein disulfide-isomerase family, leading to some ambiguity in the nomenclature. This enzyme belongs to the family of oxidoreductases, specifically those acting on a sulfur group of donors with a disulfide as acceptor. The systematic name of this enzyme class is glutathione:protein-disulfide oxidoreductase. Other names in common use include glutathione-insulin transhydrogenase, insulin reductase, reductase, protein disulfide (glutathione), protein disulfide transhydrogenase, glutathione-protein disulfide oxidoreductase, protein disulfide reductase (glutathione), GSH-insulin transhydrogenase, protein-disulfide interchange enzyme, protein-disulfide isomerase/oxidoreductase, thiol:protein-disulfide oxidoreductase, and thiol-protein disulphide oxidoreductase. This enzyme participates in glutathione metabolism.
Sulfoaildenafil (thioaildenafil) is a synthetic drug that is a structural analog of sildenafil (Viagra). It was first reported in 2005, and it is not approved by any health regulation agency. Like sildenafil, sulfoaildenafil is a phosphodiesterase type 5 inhibitor. Sulfoaildenafil has been found as an adulterant in a variety of supplements which are sold as "natural" or "herbal" sexual enhancement products. A range of designer analogues of USA FDA-approved inhibitors of type-5 cGMP-specific phosphodiesterase (PDE5), such as sildenafil and vardenafil, have been detected in recent years as adulterants in over-the-counter herbal aphrodisiac products and dietary supplements, in an apparent attempt to circumvent both the legal restrictions on sale of erectile dysfunction drugs, which are prescription-only medicines in most Western countries, and the patent protection which prevents sale of these drugs by competitors except under license to their inventors. These compounds have been demonstrated to display PDE5 inhibitory activity in vitro and presumably have similar effects when consumed, but have undergone no formal testing in either humans or animals, and as such represent a significant health risk to consumers of these products due to their unknown safety profile. Some attempts have been made to ban these drugs as unlicensed medicines, but progress has been slow so far, as even in those jurisdictions which have laws targeting designer drugs, the laws are drafted to ban analogues of illegal drugs of abuse, rather than analogues of prescription medicines.
== Causes == PAN has no association with anti-neutrophil cytoplasmic antibodies, but about 30% of people with PAN have chronic hepatitis B and deposits containing HBsAg-HBsAb complexes in affected blood vessels, indicating an immune complex-mediated cause in that subset. Infection with the hepatitis C virus and HIV are occasionally discovered in people affected by PAN. PAN has also been associated with underlying hairy cell leukemia. The cause remains unknown in the remaining cases; there may be causal and clinical distinctions between classic idiopathic PAN, the cutaneous forms of PAN, and PAN associated with chronic hepatitis. In children, cutaneous PAN is frequently associated with streptococcal infections, and positive streptococcal serology is included in the diagnostic criteria.
Andrews, Richard Mowery. "Social Structures, Political Elites and Ideology in Revolutionary Paris, 1792–94: A Critical Evaluation of Albert Soboul's' Les sans-culottes parisiens en l'an II'," Journal of Social History (1985) 19#1 pp. 71–112. in JSTOR Furet, François and Mona Ozouf, eds. A Critical Dictionary of the French Revolution (1989), pp. 393–99 Palmer, Robert Roswell (1958), Twelve Who Ruled. The Making of the Sans-culottes: Democratic Ideas and Institutions in Paris ...by R.B. Rose (1983) Salmon, Jean (1975), Curés Sans-culottes En Province : 1789-1814. Langres: Diffusion Museé Saint-Didier. Sonenscher, Michael. Sans-Culottes: An Eighteenth-Century Emblem in the French Revolution (Princeton University Press, 2008). Pp. 493. Williams, Gwyn A (1969), Artisans and Sans-culottes: Popular Movements in France and Britain during the French Revolution. Foundations of Modern History. New York: Norton. Woloch, Isser, and Peter McPhee. "A Revolution in Political Culture" in McPhee, ed., A Companion to the French Revolution (2012) pp. 435–453
Sources: en.wikipedia.org
Early submarines had few navigation aids, but modern subs have a variety of navigation systems. Modern military submarines use an inertial guidance system for navigation while submerged, but drift error unavoidably builds over time. To counter this, the crew occasionally uses the Global Positioning System to obtain an accurate position. The periscope—a retractable tube with a prism system that provides a view of the surface—is only used occasionally in modern submarines, since the visibility range is short. The Virginia-class and Astute-class submarines use photonics masts rather than hull-penetrating optical periscopes. These masts must still be deployed above the surface, and use electronic sensors for visible light, infrared, laser range-finding, and electromagnetic surveillance. One benefit to hoisting the mast above the surface is that while the mast is above the water the entire sub is still below the water and is much harder to detect visually or by radar.
Many affected infants also have distinctive abnormalities of the head and facial (craniofacial) area. Many of the physical features associated with the disorder are congenital. In most cases, premature closure of fibrous joints (sagittal sutures) between certain bones (parietal bones) of the skull may restrict lateral growth of the skull, causing it to appear abnormally long and narrow that is disproportionate to the body size. In addition, the forehead may be abnormally prominent and the face may be triangular shaped with a hypo plastic mid face, pointed chin. Infants with this disorder may also have abnormally flat cheeks and cheekbones, large ears, prominent mouth with widely spread lips, and or underdeveloped upper jaw bones (maxillary hypoplasia). In addition, in some cases, the teeth may be abnormally crowded together, particularly toward the front of the mouth (anterior crowding) and as a result, the upper result, the upper jaw and lower teeth may not meet properly, they might be abnormally crowded together.
The operating principle of CCC equipment requires a column consisting of a tube coiled around a bobbin. The bobbin is rotated in a double-axis gyratory motion (a cardioid), which causes a variable g-force to act on the column during each rotation. This motion causes the column to see one partitioning step per revolution and components of the sample separate in the column due to their partitioning coefficient between the two immiscible liquid phases. "High-performance" countercurrent chromatography (HPCCC) works in much the same way as HSCCC. A seven-year research and development process produced HPCCC instruments that generated 240 g's, compared to the 80 g's of the HSCCC machines. This increase in g-force and larger bore of the column has enabled a ten-fold increase in throughput, due to improved mobile phase flow rates and a higher stationary phase retention. Countercurrent chromatography is a preparative liquid chromatography technique, however with the advent of the higher-g HPCCC instruments it is now possible to operate instruments with sample loadings as low as a few milligrams, whereas in the past hundreds of milligrams had been necessary. Major application areas for this technique include natural product purification and drug development.
Public health authorities in Western Australia issued an emergency alert for a stretch of road measuring about 1,400 kilometres (870 miles) after a capsule containing caesium-137 was lost in transport on 25 January 2023. The 8 millimetres (0.3 inches) capsule contained a small quantity of the radioactive material when it disappeared from a truck. The State Government immediately launched a search, with the WA Department of Health's chief health officer Andrew Robertson warning an exposed person could expect to receive the equivalent of "about 10 X-rays an hour". Experts warned, if the capsule were found, the public should stay at least 5 metres (16 feet) away. The capsule was found on 1 February 2023.
planets in the habitable zones of stars with low metallicity are the best targets to search for complex life on land." A university reports a study (29 Mar) affirming the high level of economic losses from biological invasions, showing they have risen to the level of economic damage costs from floods or earthquakes, which are also rising. 19 April A bolide is observed over Ukraine and Belarus for about five seconds. It is first observed at an altitude of 98 km above Velyka Dymerka, then passes directly above Kyiv at an altitude of 80 km and continues to the southwest with a speed of 29 km/s. A bright flare occurs at an altitude of 38 km, when the bolide's absolute magnitude reaches approximately −18. The likely cause of grey hair is shown to be pigment-making cells losing their ability to mature into melanocytes. Researchers show parrots can and enjoy to use a videocalling system. A study with mice shows that microplastics pass the blood–brain barrier (BBB), entering and accumulating in the brain, and identifies a key determinant for whether or not they pass the BBB. 20 April A new 29-year record of ice sheet mass in Greenland and Antarctica is published as part of the IMBIE collaboration. It finds that the combined ice loss in these regions has more than tripled since the early 1990s, with 2019 seeing the greatest losses of any year on record. These findings have implications for future sea level rise.
Sources: en.wikipedia.org
Akan trade with European states began after contact with the Portuguese in the 15th century. European contact was by the Portuguese people, who came to the Gold Coast region in the 15th century to trade. The Portuguese then established the Portuguese Gold Coast (Costa do Ouro), focused on the availability of gold. The Portuguese built a trading lodge at a coastal settlement called Anomansah ("the perpetual drink"), which they renamed São Jorge da Mina. In 1481, King John II of Portugal commissioned Diogo de Azambuja to build Elmina Castle, which was completed in three years. By 1598, the Dutch had joined the Portuguese in the gold trade, establishing the Dutch Gold Coast (Nederlandse Bezittingen ter Kuste van Guinea – "Dutch properties at the Guinea coast") and building forts at Fort Komenda and Kormantsi. In 1617, the Dutch captured Elmina Castle from the Portuguese and Axim in 1642 (Fort St Anthony). European traders had joined in gold trading by the 17th century, including the Swedes, establishing the Swedish Gold Coast (Svenska Guldkusten), and Denmark–Norway, establishing the Danish Gold Coast (Danske Guldkyst or Dansk Guinea). European traders participated in the Atlantic slave trade in this area. More than 30 forts and castles were built by the merchants. The Germans established the Brandenburger Gold Coast or Groß Friedrichsburg. In 1874, Great Britain established control over some parts of the country, assigning these areas the status of the British Gold Coast. Military engagements occurred between the British colonial powers and Akan nation-states.
Most hematology analyzers provide a five-part differential, enumerating neutrophils, lymphocytes, monocytes, eosinophils and basophils. Some instruments can also count immature granulocytes and nucleated red blood cells. If a six-part differential is provided, the IG or immature granulocyte category consists of promyelocytes, myelocytes and metamyelocytes. Hematology analyzers measure various properties of white blood cells, such as impedance, light scattering parameters, and staining reactions. This data is analyzed and plotted on a scattergram, forming distinct clusters which correspond to white blood cell types. The analyzer counts many more cells than are counted in a manual differential, resulting in improved precision. If abnormal features or cell populations that the analyzer cannot identify are present, the instrument can flag the results for manual blood smear review.
And while it had been speculated that the availability of such treatment options might change public perception of the risks associated with drug use and might lead to an increase in illicit drug use, the incidence of heroin abuse in Switzerland has declined sharply since the introduction of heroin-assisted treatment. As a study published in The Lancet concluded:
The PRs are expressed widely throughout the body, including in the uterus, cervix, vagina, fallopian tubes, breasts, fat, skin, pituitary gland, hypothalamus, and elsewhere throughout the brain. Through activation of the PRs (as well as the mPRs), progesterone has many effects, including the following:
Sources: en.wikipedia.org
Nicotinamide mononucleotide is a nucleotide intermediate in the biosynthesis of NAD+. It consists of nicotinamide attached to a ribose phosphate unit. NMN occurs naturally in cells and is present at low levels in some foods.
NMN is a direct precursor in the NAD+ salvage pathway. Enzymes called NMNAT convert NMN into NAD+, a coenzyme used in metabolism and cell signaling. Raising NMN may increase NAD+ in some experimental settings, but the effect depends on tissue and organism.
No. Nicotinamide riboside is a related compound that lacks the phosphate group present in NMN. Cells can convert nicotinamide riboside into NMN, and both compounds feed into NAD+ production through overlapping routes.
NMN is nicotinamide mononucleotide, a nucleotide intermediate in NAD+ biosynthesis. It occurs naturally in cells and is also produced commercially as a supplement ingredient.